Cover Image

Effect of tyrosine kinase inhibitors on the cytotoxic activity against HIV-1 infection

Saved in:

Bibliographic Details
Main Authors:	S. Rodríguez-Mora (Author), G. Bautista (Author), E. Mateos (Author), V. García (Author), J.L. Steegmann (Author), J. Ambrosioni (Author), Nuria Climent (Author), F. Cervantes (Author), J.M. Miró (Author), M. Plana (Author), J. Alcamí (Author), M. Coiras (Author)
Format:	Book
Published:	Elsevier, 2017-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

14 Treatment with tyrosine kinase inhibitors make PBMCs from patients with chronic myeloid leukemia less susceptible to HIV-1 infection: control of CD4+ T cell activation to control HIV-1 replication
by: Mercedes Bermejo, et al.
Published: (2017)

CD4 T cells from patients with chronic myeloid leukemia are resistant to HIV-1 proviral integration and transcription after prolonged withdrawal of treatment with tyrosine kinase inhibitors
by: Lorena Vigón, et al.
Published: (2019)

Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection
by: Núria Climent, et al.
Published: (2019)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
by: Andrea Rodríguez-Agustín, et al.
Published: (2023)

Peripheral blood lymphocytes from patients with chronic myeloid leukemia on treatment with dasatinib are resistant to HIV-1 infection
by: M. Coiras, et al.
Published: (2015)

Tyrosine kinase inhibition: the new front in HIV cure efforts
by: V. Planelles, et al.
Published: (2019)

Transport of six tyrosine kinase inhibitors: active or passive?
by: Richard J. Honeywell, et al.
Published: (2016)

Quinazolin-4(3H)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity
by: Tebyan O. Mirgany, et al.
Published: (2021)

Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
by: Bourn J, et al.
Published: (2018)

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later
by: Max Robles-Nasta, et al.
Published: (2024)

ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors
by: Godefridus J. Peters, et al.
Published: (2016)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
by: Wu J, et al.
Published: (2020)

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro
by: Skoglund K, et al.
Published: (2013)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
by: Domenico Ribatti
Published: (2010)

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
by: Zahra Moradpour, et al.
Published: (2019)

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
by: Zhao Y, et al.
Published: (2015)

Subcellular localization of several structurally different tyrosine kinase inhibitors
by: Richard Honeywell, et al.
Published: (2018)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024)

Pharmacovigilance study of tyrosine kinase inhibitors: Analysis of adverse reactions
by: Antoan Rangelov, et al.
Published: (2024)

Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
by: Made Putra Semadhi, et al.
Published: (2017)

Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
by: Pitsiou G, et al.
Published: (2014)

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
by: Noor E. Verhagen, et al.
Published: (2023)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
by: Julie Bolcaen, et al.
Published: (2021)

Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia
by: Luma Al-Ali, et al.
Published: (2024)

Tyrosine kinase inhibitors induced scrotal ulcerations: Report of 2 cases
by: Abhipsa Samal, et al.
Published: (2023)

Use of etanercept in management of tyrosine kinase-inhibitor-induced erythema nodosum
by: Erisa Alia, MD, et al.
Published: (2020)

Bruton's tyrosine kinase inhibitor associated localized extremity edema and erythema
by: Shannon Meledathu, BS, et al.
Published: (2024)

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
by: Maddalena Centanni, et al.
Published: (2020)

Cardiovascular safety of tyrosine kinase inhibitors: Putting their "QT-phobia" in perspective
by: Rashmi Shah
Published: (2016)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
by: Jaehee V. Shim, et al.
Published: (2023)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
by: Harpinder K. Brar, et al.
Published: (2022)

Tyrosine Kinases and Phosphatases: Enablers of the Porphyromonas gingivalis Lifestyle
by: Richard J. Lamont, et al.
Published: (2022)

Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia
by: Marta Romo-González, et al.
Published: (2020)

Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of in-silico and in-vitro cytotoxicity methods
by: Rezvan Rezaee Nasab, et al.
Published: (2018)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
by: Abbaspour Babaei M, et al.
Published: (2016)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
by: Krisztina Futosi, et al.
Published: (2023)

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton's tyrosine kinase inhibitor
by: Alison H. Kucharik, MD, et al.
Published: (2024)

Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
by: Timothy J. Turner, et al.
Published: (2024)